Optimisation of Mechanical Insufflation:Exsufflation

Neuromuscular Diseases Clinical Trial

— MIE2  

Official title:

Investigating Methods to Improve Secretion Clearance Using Mechanical Insufflation:Exsufflation in Patients With Neuromuscular Disease.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04163198
• Other study ID #: 1.0
• Status: Recruiting
• Phase: N/A
• Start date: December 19, 2019
• Est. completion date: May 31, 2025

Study information

• Verified date: March 2024
• Source: Guy's and St Thomas' NHS Foundation Trust
• Contact: Patrick Murphy, PhD
• Phone: +442071888070
• Email: patrick.murphy[@]gstt.nhs.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with neuromuscular diseases (NMD) can suffer from a range of respiratory problems due to respiratory muscle weakness. Cough muscle weakness means secretion clearance from the airways can be problematic, a source of infection, and importantly a cause of death, in this patient group. Therefore, these patients are often supported with devices to aid clearance, such as mechanical insufflation-exsufflation (MIE). Although evidence supports the use of these devices, the optimal technique or settings on the device are not clear. Increasingly, higher pressures are used during MIE and recent work has demonstrated that there may be a physiological benefit to this. However, higher pressures increase the risk of causing lung collapse and may cause detriment to blood flow back to the heart, which is important as NMD patients frequently have concurrent heart muscle weakness. Further, recent work has demonstrated that higher pressures can cause closure of the throat, which is counter-productive in secretion clearance.

The overall aim of this study is to investigate methods to manipulate MIE to improve secretion clearance in patients with NMD. The questions it seeks to answer are:

(i) how can we maximally improve lung recruitment during inspiration, whilst maintaining patient comfort and lower pressures (ii) what is the smallest pressure difference required in expiration to achieve an improvement in cough (iii) do these proposed changes to MIE also cause throat closure (iv) what factors do patients believe contribute to their adherence to MIE therapy?

Patients with slowly progressive or stable neuromuscular diseases will be included in the study. Participation will involve two visits to the Lane Fox Respiratory Unit, each lasting approximately four hours. Patients will be recruited from specialist neuromuscular respiratory clinics by their clinical teams.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: May 31, 2025
• Est. primary completion date: March 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Stable or slowly progressive neuromuscular disease

• Respiratory muscle weakness (FVC <60%, snip <60%, sleep disordered breathing)

• Clinical evidence of respiratory secretions or cough peak expiratory flow <270 and history of lower respiratory tract infection

• Documented clinical stability by supervising clinician

Exclusion Criteria:

• Rapidly progressive neuromuscular disease (such as motor neuron disease)

• Decompensated respiratory failure (pH < 7.35)

• Pregnancy

• Aged <18

• Change in ventilator settings in preceding 4 weeks

• Significant physical or psychiatric co-morbidity that would prevent compliance with trial protocol

Related Conditions & MeSH terms

• Neuromuscular Diseases

Intervention

Device:
• Insufflation
Patients will receive different inspiratory (Ti) and expiratory (Te) times and inspiratory flows, at a fixed insufflation and exsufflation pressure. Optimum insufflation pressure will be determined by measuring maximal inspiratory capacity.
• Exsufflation
Patients will receive different exsufflation pressures at fixed insufflation pressure.

Locations

Country	Name	City	State
United Kingdom	Guys & St. Thomas' NHS Foundation Trust	London

Sponsors (2)

Lead Sponsor	Collaborator
Guy's and St Thomas' NHS Foundation Trust	Royal Brompton & Harefield NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cough peak expiratory flow (cPEF)	Change in cPEF with different modalities of MI-E	2 days